We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.
- Authors
Galanis, Evanthia; Buckner, Jan C; Maurer, Matthew J; Kreisberg, Jeffrey I; Ballman, Karla; Boni, J; Peralba, Josep M; Jenkins, Robert B; Dakhil, Shaker R; Morton, Roscoe F; Jaeckle, Kurt A; Scheithauer, Bernd W; Dancey, Janet; Hidalgo, Manuel; Walsh, Daniel J; North Central Cancer Treatment Group
- Abstract
Temsirolimus (CCI-779) is a small-molecule inhibitor of the mammalian target of rapamycin (mTOR) and represents a rational therapeutic target against glioblastoma multiforme (GBM).
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Vol 23, Issue 23, p5294
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.2005.23.622